Clinical  	Clinical  	 JJ	B-NP
characteristics  	characteristics  	 NNS	I-NP
of  	of  	 IN	I-NP
IgG4-related  	IgG4-related  	 CD	I-NP
retroperitoneal  	retroperitoneal  	 JJ	I-NP
fibrosis  	fibrosis  	 NN	I-NP
To  	To  	 TO	O
explore  	explore  	 VB	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
characteristics  	characteristics  	 NNS	I-NP
of  	of  	 IN	I-NP
IgG4-related  	IgG4-related  	 FW	I-NP
retroperitoneal  	retroperitoneal  	 FW	I-NP
fibrosis  	fibrosis  	 FW	I-NP
( 	( 	 -LRB-	O
RPF 	RPF 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
China 	China 	 NNP	O
.  	.  	 .	O
From  	From  	 IN	O
December  	December  	 NNP	O
2010  	2010  	 CD	O
to  	to  	 TO	O
September  	September  	 NNP	O
2013 	2013 	 CD	O
,  	,  	 ,	O
a  	a  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
107  	107  	 CD	O
IgG4-related  	IgG4-related  	 CD	B-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
IgG4-RD 	IgG4-RD 	 NNP	B-NP
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
reviewed  	reviewed  	 VBN	O
prospectively 	prospectively 	 RB	O
.  	.  	 .	O
Their  	Their  	 PRP$	O
clinical 	clinical 	 JJ	O
,  	,  	 ,	O
laboratory  	laboratory  	 NN	O
and  	and  	 CC	O
histopathological  	histopathological  	 JJ	B-NP
features  	features  	 NNS	I-NP
were  	were  	 VBD	O
summarized 	summarized 	 VBN	O
.  	.  	 .	O
And  	And  	 CC	O
the  	the  	 DT	O
treatment  	treatment  	 NN	B-NP
responses  	responses  	 NNS	I-NP
were  	were  	 VBD	O
analyzed 	analyzed 	 VBN	O
.  	.  	 .	O
Among  	Among  	 IN	O
them 	them 	 PRP	O
,  	,  	 ,	O
22  	22  	 CD	O
RPF  	RPF  	 NN	B-NP
cases  	cases  	 NNS	I-NP
were  	were  	 VBD	O
identified 	identified 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
male-to-female  	male-to-female  	 JJ	B-NP
ratio  	ratio  	 NN	I-NP
and  	and  	 CC	O
age  	age  	 NN	O
were  	were  	 VBD	O
4.5 	4.5 	 CD	O
:  	:  	 :	O
1  	1  	 CD	O
and  	and  	 CC	O
63  	63  	 CD	O
±  	±  	 CD	O
11  	11  	 CD	O
years  	years  	 NNS	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
follow-up  	follow-up  	 JJ	B-NP
period  	period  	 NN	I-NP
was  	was  	 VBD	O
3-28  	3-28  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
onset  	onset  	 NN	B-NP
symptom  	symptom  	 NN	I-NP
was  	was  	 VBD	O
low  	low  	 JJ	O
back  	back  	 JJ	O
pain  	pain  	 NN	O
( 	( 	 -LRB-	O
55 	55 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Multiple  	Multiple  	 JJ	B-NP
organ  	organ  	 NN	I-NP
involvements  	involvements  	 NNS	I-NP
were  	were  	 VBD	O
documented  	documented  	 VBN	O
in  	in  	 IN	O
20  	20  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
91 	91 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
including  	including  	 VBG	B-NP
lymphadenopathy  	lymphadenopathy  	 NNS	I-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
9 	9 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
aortitis  	aortitis  	 NNS	B-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
8 	8 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
sialadenitis  	sialadenitis  	 NNS	B-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
7 	7 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
dacryoadenitis  	dacryoadenitis  	 NNS	B-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
5 	5 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
autoimmune  	autoimmune  	 JJ	B-NP
pancreatitis  	pancreatitis  	 NNS	I-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
4 	4 	 LS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Allergic  	Allergic  	 JJ	B-NP
histories  	histories  	 NN	I-NP
were  	were  	 VBD	O
reported  	reported  	 VBN	B-NP
by10  	by10  	 CD	I-NP
subjects  	subjects  	 NNS	I-NP
( 	( 	 -LRB-	O
46 	46 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Eosinophilia  	Eosinophilia  	 NNP	B-NP
was  	was  	 VBD	O
present  	present  	 JJ	O
in  	in  	 IN	O
6  	6  	 CD	O
subjects  	subjects  	 NNS	B-NP
( 	( 	 -LRB-	O
27 	27 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Serum  	Serum  	 NNP	B-NP
IgG4  	IgG4  	 NNP	I-NP
levels  	levels  	 NNS	I-NP
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
elevated  	elevated  	 VBD	O
in  	in  	 IN	O
all  	all  	 DT	O
subjects 	subjects 	 NNS	B-NP
.  	.  	 .	O
Serum  	Serum  	 JJ	B-NP
total  	total  	 JJ	I-NP
IgE  	IgE  	 JJ	I-NP
level  	level  	 NN	I-NP
was  	was  	 VBD	O
elevated  	elevated  	 VBN	O
in  	in  	 IN	O
12 	12 	 CD	O
/ 	/ 	 CD	O
13  	13  	 CD	O
tested  	tested  	 CD	B-NP
subjects 	subjects 	 NNS	I-NP
.  	.  	 .	O
Tissue  	Tissue  	 NN	B-NP
biopsies  	biopsies  	 NNS	I-NP
of  	of  	 IN	O
12  	12  	 CD	O
subjects  	subjects  	 NNS	B-NP
revealed  	revealed  	 VBD	O
massive  	massive  	 JJ	B-NP
lymphocytic  	lymphocytic  	 JJ	I-NP
infiltration  	infiltration  	 NN	I-NP
and  	and  	 CC	O
obvious  	obvious  	 JJ	O
tissue  	tissue  	 NN	O
fibrosis 	fibrosis 	 NN	O
.  	.  	 .	O
Immunohistochemical  	Immunohistochemical  	 JJ	B-NP
staining  	staining  	 NN	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
massive  	massive  	 JJ	B-NP
infiltration  	infiltration  	 NN	I-NP
of  	of  	 IN	I-NP
IgG4-positive  	IgG4-positive  	 CD	I-NP
plasma  	plasma  	 JJ	I-NP
cell 	cell 	 NN	I-NP
.  	.  	 .	O
Glucocorticoid  	Glucocorticoid  	 NNP	B-NP
was  	was  	 VBD	O
administrated  	administrated  	 VBN	O
in  	in  	 IN	O
all  	all  	 DT	O
subjects 	subjects 	 NNS	B-NP
.  	.  	 .	O
Most  	Most  	 JJS	B-NP
subjects  	subjects  	 NNS	I-NP
received  	received  	 VBD	O
combined  	combined  	 VBN	O
therapy  	therapy  	 NN	O
with  	with  	 IN	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
or  	or  	 CC	O
tamoxifen 	tamoxifen 	 NN	B-NP
.  	.  	 .	O
IgG4-related  	IgG4-related  	 NNP	B-NP
RPF  	RPF  	 NNP	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
systemic  	systemic  	 JJ	B-NP
autoimmune  	autoimmune  	 JJ	I-NP
disease  	disease  	 NN	I-NP
with  	with  	 IN	O
favorable  	favorable  	 JJ	O
responses  	responses  	 NNS	O
to  	to  	 TO	O
the  	the  	 DT	O
treatments  	treatments  	 NNS	O
of  	of  	 IN	O
glucocorticoid  	glucocorticoid  	 NN	B-NP
and  	and  	 CC	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
